Anzeige
❌
Mehr »
Freitag, 09.10.2026 - Börsentäglich über 12.000 News
Elevate Sercive Group: Neue Expertise für den nächsten Wachstumsschritt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
NT

WKN: A425ME | ISIN: US80512Q6008 | Ticker-Symbol: 80W0
München
09.10.26 | 08:13
0,764 Euro
-17,00 % -0,157
Branche
Software
Aktienmarkt
Sonstige
1-Jahres-Chart
NEXENTIS TECHNOLOGIES INC Chart 1 Jahr
5-Tage-Chart
NEXENTIS TECHNOLOGIES INC 5-Tage-Chart

Aktuelle News zur NEXENTIS TECHNOLOGIES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiNexentis subsidiary deploys drug discovery platform on Google Cloud8
NEXENTIS TECHNOLOGIES Aktie jetzt für 0€ handeln
MiNexentis Technologies Inc.: Nexentis: MitoCareX Bio Deploys its Computational Drug Discovery Infrastructure on Google Cloud352Deployment on Google Cloud Platform is designed to enhance computational capacity, data governance and operational flexibility as MitoCareX advances its drug discovery programs Ness Ziona, Israel...
► Artikel lesen
DiNexentis Technologies Inc. - 8-K, Current Report1
24.09.Nexentis beruft Experten für computergestützte Chemie in wissenschaftlichen Beirat1
24.09.Nexentis Technologies Inc.: Nexentis: MitoCareX Strengthens Its Computational Drug Discovery Capabilities with Appointment of Prof. Dan T. Major to Scientific Advisory Board5
23.09.Nexentis Technologies Inc.: Nexentis: MitoCareX Evaluates Expanded Protein Capabilities to Enhance Flexibility and Support Future Drug Discovery2
13.08.Nexentis Technologies Inc. - 10-Q, Quarterly Report2
28.07.Nexentis subsidiary selects candidate for drug discovery program-
28.07.Nexentis Technologies Inc.: Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign451Following its broad structural analysis of the human SLC transport protein family, MitoCareX advances from a pool of candidates to a prioritized target, reflecting continued execution of its MITOLINE-...
► Artikel lesen
13.07.Nexentis Technologies Inc. - S-1, General form for registration of securities1
07.07.Nexentis Technologies Inc.: Nexentis Subsidiary MitoCareX Bio Advances SLC Transporter Drug Discovery with Broad Analysis and International AI Initiative1
29.06.Nexentis erhält vorzeitige Teilrückzahlung für deutsches Solarprojekt2
29.06.Nexentis Technologies Inc.: Nexentis Announces Monetization of Part of its Melz Solar Investment at $14.5 Million Project Valuation - Significant Premium to Initial Investment429Neve Yarak, Israel, June 29, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based...
► Artikel lesen
23.06.Nexentis Technologies Soars 156% Before Falling 46% After Hours - Here's Why NXTS Stock Is Trending6
22.06.Nexentis Technologies Inc. - 8-K, Current Report3
22.06.Nexentis Technologies Stock Skyrockets 247% On AI Drug Discovery Collaboration3
22.06.Nexentis Technologies Inc.: Nexentis Technologies Announces International AI Drug Discovery Initiative Between MitoCareX Bio and Boltz to Accelerate Novel SLC Small-Molecule Discovery534MITOLINE- -Enabled 3D Structural Modeling and Boltz AI Capabilities to Be Combined by MitoCareX in a Synergistic Virtual Screening Campaign for selected Transporter Targets Neve Yarak, Israel, June...
► Artikel lesen
17.06.Nexentis subsidiary completes analysis of transport proteins1
17.06.Nexentis Technologies Inc.: Nexentis: Subsidiary MitoCareX Bio Successfully Completed Broad Analysis of SLC Transport Proteins to Support Discovery of Hard-to-Treat Cancers and Metabolic Diseases1
12.06.Nexentis Technologies Inc. - 8-K, Current Report2
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1